logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Hualan Vaccine: Currently focusing on research and production of human vaccines.

date
21/05/2025
Huahlan vaccines stated on the interactive platform that the company is currently focusing on the research and production of human vaccines, while also closely monitoring the latest developments in the market for animal vaccines.
Latest
2 m ago
Nvidia's "beloved son" CoreWeave soared by more than 14% in intra-day trading today, hitting a new record high again; it is currently up more than 11%, with a cumulative increase of over 150% since its initial public offering.
2 m ago
The Chinese Ambassador to Ireland met with the Minister for Finance and Chair of the Eurogroup to exchange views on supporting the development of the Asian Infrastructure Investment Bank and strengthening trade cooperation.
3 m ago
China Telecom (00728.HK) will distribute a final dividend of 0.0927 yuan per share on July 18th.
3 m ago
Evercore ISI Group: Reiterate Match Group (MTCH.US) rating, revised from outperform to market perform, with a target price adjusted from $32.00 to $32.00.
4 m ago
UBS: Maintains Buy rating on ALX Oncology Holdings (ALXO.US), adjusted from Buy to Buy rating, target price adjusted from $1.20 to $1.00.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.